Diazepam is a drug used to treat mild to moderate anxiety and tension and to relax muscles. It is a type of benzodiazepine. Also called Valium.
An amino acid whose role in the body has been all but a mystery appears to act as a potent seizure inhibitor in mice, according to a study by researchers at Johns Hopkins.
In a recent study, nearly half of all veterans who died from drug overdoses while prescribed opioids for pain were also receiving benzodiazepines, or benzos, which are common medications for the treatment of anxiety, insomnia and alcohol withdrawal. Veterans prescribed higher doses of benzodiazepines while concurrently receiving opioids were at greater risk of overdose death than those on lower doses of benzodiazepines.
By studying specially bred mice with specific developmental and cognitive traits resembling those seen in schizophrenia, UC San Francisco researchers have provided new evidence that abnormal rhythmic activity in particular brain cells contributes to problems with learning, attention, and decision-making in individuals with that disorder.
Alexza Pharmaceuticals, Inc. announced today that it has initiated a Phase 2a study of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS).
Approximately 71 percent of American adults drink alcohol. While alcohol interacts negatively with a number of commonly prescribed medications, little is known on a population level about the use of alcohol-interactive (AI) prescription medication among US drinkers. A new study has found that almost 42 percent of drinkers in the US population have used one or more alcohol-interactive prescription medications.
The insular cortex is an integral "hub", combining sensory, emotional and cognitive content. Not surprisingly, alterations in insular structure and function have been reported in many psychiatric disorders, such as anxiety disorders, depression, addiction and autism spectrum disorders (ASD).
A recently published clinical study in the Journal of the American Medical Association has answered an urgent question that long puzzled ER pediatricians: Is the drug lorazepam really safer and more effective than diazepam - the U.S. Food and Drug Administration-approved medication as first line therapy most often used by emergency room doctors to control major epileptic seizures in children?
A National Institutes of Health-sponsored study published in the Journal of the American Medical Association showed that lorazepam - a widely used but not yet Food and Drug Administration approved drug for children - is no more effective than an approved benzodiazepine, diazepam, for treating pediatric status epilepticus.
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.
The sedative drugs diazepam (Valium) and lorazepam (Ativan) are equally effective in treating the prolonged seizures known as status epilepticus in children, according to a randomized, controlled study by a multi-institution team of researchers with the Pediatric Emergency Care Applied Research Network, including an expert from the Perelman School of Medicine at the University of Pennsylvania.
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Diazepam Oral Solution (Concentrate), 5 mg/mL, a Schedule C-IV controlled drug.
Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.
Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.
Acorda Therapeutics, Inc. will present new research data on AMPYRA (dalfampridine) Extended Release Tablets, 10 mg at the 5th Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis, being held in Orlando, FL, May 29 - June 1.
Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.
Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics, Inc. today announced that the Company has completed the acquisition of Neuronex, Inc., a privately held company developing a nasal spray formulation of diazepam. Under the terms of the agreement, Acorda paid $6.8 million to Neuronex to complete the acquisition.
Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.
Benzodiazepines are associated with an increased risk for developing pneumonia, as well as an increased risk for dying from pneumonia, research shows.